Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

被引：3
|
作者：
Elshaer, Amani [1 ]
Chascsa, David M. H. [2 ,3 ]
Lizaola-Mayo, Blanca C. [2 ,3 ]
机构：
[1] Mayo Clin, Dept Internal Med, Scottsdale, AZ 85054 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Scottsdale, AZ 85054 USA
[3] Mayo Clin, Transplant Ctr, Dept Med, Scottsdale, AZ 85054 USA
来源：
LIFE-BASEL | 2024年 / 14卷 / 07期
关键词：
metabolic-associated steatotic liver disease; fibrosis; cirrhosis; obesity; weight loss; lifestyle modification; pharmacotherapy; bariatric surgery; LIFE-STYLE MODIFICATION; CLINICAL-PRACTICE UPDATE; GLUCAGON-LIKE PEPTIDE-1; CORONARY-HEART-DISEASE; FATTY LIVER; BARIATRIC SURGERY; INSULIN-RESISTANCE; WEIGHT-LOSS; NONALCOHOLIC STEATOHEPATITIS; AMERICAN ASSOCIATION;
D O I：
10.3390/life14070844
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a liver disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading to increased patient risk of various complications. Recent research has been focused on new therapeutic strategies to reduce the incidence of MASLD and provide effective treatment plans to prevent further irreversible liver damage. The treatment approach is multifactorial, with a primary focus on weight loss and management of underlying comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing research is exploring new pharmacological therapies that could enhance the treatment of MASLD.
引用
收藏
页数：21
相关论文
共 50 条
  • [1] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025,
  • [2] Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Liu, Huan
    Yerevanian, Armen
    Westerhoff, Maria
    Hastings, Margaret H.
    Guerra, Justin Ralph Baldovino
    Zhao, Meng
    Svensson, Katrin J.
    Cai, Bishuang
    Soukas, Alexander A.
    Rosenzweig, Anthony
    DIABETES, 2024, 73 (02) : 260 - 279
  • [3] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [4] Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine MASLD
    Stefan, Norbert
    Targher, Giovanni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 226 - 227
  • [5] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [6] INSULIN RESISTANCE IS A PREDICTOR OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND MASLD-ASSOCIATED FIBROSIS
    Kim, David S.
    Ismail, Mohamed
    Abboud, Yazan
    Khan, Wajiha
    Le, Alexander
    Pyrsopoulos, Nikolaos T.
    Kim, Hyunseok
    Hajifathalian, Kaveh
    GASTROENTEROLOGY, 2024, 166 (05) : S1657 - S1657
  • [7] Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Markowska, Julia
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Dragan, Magdalena
    Kondracka, Adrianna
    Gondek, Ewa
    Oniszczuk, Tomasz
    Oniszczuk, Anna
    MOLECULES, 2024, 29 (22):
  • [8] Exploring Autoantibodies as Predictors of Severe Fibrosis or Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Response
    Faisal, Nabiha
    Minuk, Gerald
    CANADIAN LIVER JOURNAL, 2024, 7 (04): : 417 - 418
  • [9] Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Singh, Avneet
    Buckholz, Adam
    Kumar, Sonal
    Newberry, Carolyn
    NUTRIENTS, 2024, 16 (05)
  • [10] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Chan, Wah-Kheong
    Chuah, Kee-Huat
    Rajaram, Ruveena Bhavani
    Lim, Lee-Ling
    Ratnasingam, Jeyakantha
    Vethakkan, Shireene Ratna
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (03) : 197 - 213
12345